Skip to content

IDEXX Laboratories Inc

US · IDXX #543 by market cap Listed 1970
676.21 -13.44 -1.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 8 in the most recent period (2026/Q4).
  • Total institutional ownership (as a % of shares) was little changed.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
95.84% -0.07pp
Institutions
1,622 -8
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund81.79%
Hedge Fund4.11%
Public Company3.50%
Government Pension Fund2.88%
Private Company1.53%
Family Office/Trust0.55%
Sovereign Wealth Fund0.54%
Insurance Company0.42%
Individual/Insider0.25%
Other4.44%

Top holders as of 2026-09-30

BlackRock 10.28% · 8.10M sh
Vanguard Capital Management, LLC 7.12% · 5.61M sh
Vanguard Portfolio Management, LLC 5.02% · 3.96M sh
State Street Global Advisors 4.77% · 3.76M sh
Invesco Capital Management LLC 3.77% · 2.97M sh
Geode Capital Management, LLC 3.33% · 2.62M sh
Baron Capital Group, Inc. 2.26% · 1.78M sh
UBS Asset Management 1.89% · 1.49M sh
T. Rowe Price Group, Inc. 1.75% · 1.38M sh
William Blair Investment Management, LLC 1.55% · 1.22M sh
Arrowstreet Capital, Limited Partnership 1.73% · 1.36M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 35 buys · 15 sells

NameRoleStake
Jonathan Mazelsky Executive Chairperson 0.11%
Brian McKeon Former Executive VP & Special Advisor 0.03%
Nimrata Hunt Former Executive Vice President of Global Strategy & Commercial 0.02%
Michael Erickson Chief Executive Officer 0.02%
George Fennell Executive Vice President of Global CAG Commercial 0.02%
Lawrence Kingsley Lead Independent Director 0.01%
Sophie Vandebroek Independent Director 0.01%
Sharon Underberg Executive VP, General Counsel, & Corporate Secretary 0.01%
Andrew Emerson Chief Financial Officer 0.01%
Michael Lane Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 George Fennell Executive Vice President of Global CAG Commercial Derivative Exercise and Retained +1,749 $141.60–206.94
2026-11-03 Daniel Junius Independent Director Open Market Disposition -1,200 $701.69–705.78
2026-11-03 Daniel Junius Independent Director Intent to Sell (Form 144) -1,200 $691.67–705.78
2026-11-03 Sharon Underberg Executive VP, General Counsel, & Corporate Secretary Derivative Exercise and Sale -8,906 $288.78–690.02
2026-11-03 Jonathan Mazelsky Executive Chairperson Derivative Exercise and Sale -25,140 $178.26–711.95
2026-11-03 Michael Lane Executive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology Open Market Disposition -3,978 $687.46–689.70
2026-10-29 Joseph Hooley Independent Director Other Acquisition +48 $551.21
2026-09-03 Lawrence Kingsley Lead Independent Director Derivative Exercise and Sale -2,203 $114.17–532.08
2026-08-19 Andrew Emerson Chief Financial Officer Derivative Exercise and Sale -86 $178.26
2026-08-19 Andrew Emerson Chief Financial Officer Derivative Exercise and Retained +179 $178.26
2026-07-29 Joseph Hooley Independent Director Other Acquisition +49 $558.80
2026-05-31 George Fennell Executive Vice President of Global CAG Commercial Derivative Exercise and Sale -284 $566.79
2026-05-31 George Fennell Executive Vice President of Global CAG Commercial Derivative Exercise and Retained +355 --
2026-05-11 Daniel Junius Independent Director Other Derivative Acquisition +234 --
2026-05-11 Daniel Junius Independent Director Other Derivative Acquisition +525 $533.92
2026-05-11 Bruce Claflin Independent Director Other Derivative Acquisition +234 --
2026-05-11 Bruce Claflin Independent Director Other Derivative Acquisition +525 $533.92
2026-05-11 Stuart Essig Independent Director Other Derivative Acquisition +234 --
2026-05-11 Stuart Essig Independent Director Other Derivative Acquisition +525 $533.92
2026-05-11 Joseph Hooley Independent Director Other Derivative Acquisition +234 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:16 · For reference only, not investment advice and not tailored to your situation.

IDEXX Laboratories Inc discussion 0 comments

Add a comment